Cascadia Capital Advises Vera Whole Health on its Strategic Investment from Leerink Transformation Partners

Vera Whole Health Logo has received debt financing from Comerica Logo

Cascadia Capital, an investment bank serving middle market clients globally, is pleased to announce that its client, Vera Whole Health (“Vera”, or the “Company”), a next-generation primary care provider focused on self-insured employers, has received a $24 million growth equity investment from a consortium of investors, led by Leerink Transformation Partners.  Cascadia served as the exclusive financial advisor to Vera in the transaction.

“Cascadia did an exceptional job positioning us in front of funds that align with our strategy and values,” said Ryan Schmid, President and CEO of Vera.  “Their deep healthcare knowledge and relationships were key to receiving multiple offers and running a process that lasted less than three months from go-to-market to close.  I couldn’t be more pleased with our results.”

Founded in 2007, Vera provides a scalable on-site medical management network that has proven abilities to drive meaningful healthcare cost savings for employers and improve overall employee health. The Company’s differentiated care model is multi-faceted and includes on-site health clinics, face-to-face health coaching and active patient management that results in industry-leading patient engagement and employee satisfaction.

Leerink Transformation Partners, a leading healthcare investment firm focused on identifying and working with companies in the healthcare technology and services sectors, recognized the Company’s strong growth trajectory and differentiated clinical care model, and together with existing investors, provided the growth equity financing to support Vera’s ongoing geographic expansion.  Vera has eight clinics in two states, and targets being in seven states by the end of 2017.

The financing represents another successful transaction for Cascadia in the Healthcare sector.  Recent notable transactions include the equity financings of BardyDX and Impel Neuropharma.

For more information about this transaction, please contact:

Kevin Cable
Managing Director
(206) 436-2518

Back to News